Repligen (NASDAQ:RGEN) released its quarterly earnings data on Thursday. The biotechnology company reported $0.42 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.28 by $0.14, MarketWatch Earnings reports. The firm had revenue of $87.46 million during the quarter, compared to analysts’ expectations of $78.11 million. Repligen had a return on equity of 5.99% and a net margin of 10.23%. Repligen updated its FY 2020
Pre-Market guidance to 1.24-1.29 EPS and its FY20 guidance to $1.24-1.29 EPS.

Repligen stock traded down $0.34 during midday trading on Friday, reaching $150.91. 1,054,320 shares of the company were exchanged, compared to its average volume of 410,098. The company has a market capitalization of $7.89 billion, a price-to-earnings ratio of 260.19, a P/E/G ratio of 5.42 and a beta of 1.06. The firm’s 50-day simple moving average is $125.27 and its 200-day simple moving average is $111.55. Repligen has a 1 year low of $72.32 and a 1 year high of $155.27. The company has a debt-to-equity ratio of 0.25, a quick ratio of 14.09 and a current ratio of 15.56.

Several research firms have issued reports on RGEN. Stifel Nicolaus increased their price objective on Repligen from $135.00 to $150.00 and gave the stock a “buy” rating in a research report on Wednesday, May 27th. Craig Hallum raised their price target on Repligen from $120.00 to $145.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. ValuEngine cut Repligen from a “buy” rating to a “hold” rating in a research report on Friday, May 1st. HC Wainwright restated a “buy” rating and issued a $151.00 price target (up previously from $143.00) on shares of Repligen in a research report on Tuesday, June 30th. Finally, BidaskClub upgraded Repligen from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 25th. Two equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $136.67.

In related news, CEO Anthony Hunt sold 46,953 shares of Repligen stock in a transaction dated Thursday, May 21st. The stock was sold at an average price of $139.77, for a total transaction of $6,562,620.81. Following the completion of the sale, the chief executive officer now owns 238,157 shares in the company, valued at approximately $33,287,203.89. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Ralf Kuriyel sold 435 shares of Repligen stock in a transaction dated Friday, May 15th. The stock was sold at an average price of $140.69, for a total value of $61,200.15. Following the sale, the vice president now owns 26,089 shares of the company’s stock, valued at approximately $3,670,461.41. The disclosure for this sale can be found here. In the last quarter, insiders have sold 92,264 shares of company stock valued at $12,168,083. 1.70% of the stock is currently owned by company insiders.

About Repligen

Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.

See Also: Coverage Ratio

Earnings History for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with's FREE daily email newsletter.